Education
About Us
Working with TipRanks
Follow Us
KYORIN Pharmaceutical Co.,Ltd. (JP:4569)
:4569
4569 Stock Chart & Stats
¥1537.00
-¥23.00(-1.53%)
At close: 4:00 PM EST
¥1537.00
-¥23.00(-1.53%)
Day’s Range― - ―
52-Week Range¥1,332.00 - ¥1,725.00
Previous CloseN/A
Volume61.80K
Average Volume (3M)127.03K
Market Cap
¥87.65B
Enterprise Value¥111.01B
Total Cash (Recent Filing)¥16.62B
Total Debt (Recent Filing)¥26.48B
Price to Earnings (P/E)8.4
Beta0.53
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.36%
Share Statistics
EPS (TTM)45.70
Shares Outstanding59,945,640
10 Day Avg. Volume147,840
30 Day Avg. Volume127,030
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.63
Price to Sales (P/S)0.66
P/FCF Ratio-39.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)84.2
Revenue Forecast (FY)¥127.00B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent top-line growth (≈8.8% year-over-year) indicates durable demand for KYORIN's marketed therapies and effective commercialization in its domestic market. Sustained revenue expansion supports R&D funding, scale advantages in manufacturing, and long-term product lifecycle investment.
Margin SustainabilityHigh gross margins (~45.8%) and improving net margin reflect durable cost control and pricing power in core product lines. Such margin resilience supports reinvestment into specialty pipelines and buffers profitability through product cycles, underpinning longer-term earnings quality.
Conservative Balance SheetA strong equity ratio and low leverage provide financial flexibility for multi-year drug development, strategic partnerships, or selective M&A. Conservative capital structure reduces refinancing risk, enabling KYORIN to endure industry R&D cycles and fund strategic initiatives without heavy debt burden.
Bears Say
Negative Free Cash FlowPersistent negative free cash flow constrains the firm’s ability to self-fund R&D, manufacturing scale-up, or dividend distributions over the medium term. Even with improving FCF trends, ongoing cash consumption may force reliance on external financing or reduce strategic optionality.
Weak Cash ConversionLow conversion of accounting earnings into cash signals working capital or receivables pressures that can persist across quarters. Structural cash conversion inefficiency reduces operational resilience, complicates investment planning, and can magnify liquidity stress during industry slowdowns.
Modest Return On EquityA mid-single-digit ROE suggests limited capital efficiency relative to high-investment pharma peers. Over the medium term, this may indicate slower shareholder value creation unless management improves product mix, pricing power, or executes higher-return development/commercial strategies.
KYORIN Pharmaceutical Co.,Ltd. News
4569 FAQ
What was KYORIN Pharmaceutical Co.,Ltd.’s price range in the past 12 months?
KYORIN Pharmaceutical Co.,Ltd. lowest stock price was ¥1332.00 and its highest was ¥1725.00 in the past 12 months.
What is KYORIN Pharmaceutical Co.,Ltd.’s market cap?
KYORIN Pharmaceutical Co.,Ltd.’s market cap is ¥87.65B.
When is KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date?
KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date is May 12, 2026 which is in 67 days.
How were KYORIN Pharmaceutical Co.,Ltd.’s earnings last quarter?
KYORIN Pharmaceutical Co.,Ltd. released its earnings results on Feb 04, 2026. The company reported ¥45.7 earnings per share for the quarter, beating the consensus estimate of N/A by ¥45.7.
Is KYORIN Pharmaceutical Co.,Ltd. overvalued?
According to Wall Street analysts KYORIN Pharmaceutical Co.,Ltd.’s price is currently Overvalued.
Does KYORIN Pharmaceutical Co.,Ltd. pay dividends?
KYORIN Pharmaceutical Co.,Ltd. pays a Semiannually dividend of ¥37 which represents an annual dividend yield of 3.36%. See more information on KYORIN Pharmaceutical Co.,Ltd. dividends here
What is KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate?
KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KYORIN Pharmaceutical Co.,Ltd. have?
KYORIN Pharmaceutical Co.,Ltd. has 59,945,640 shares outstanding.
What happened to KYORIN Pharmaceutical Co.,Ltd.’s price movement after its last earnings report?
KYORIN Pharmaceutical Co.,Ltd. reported an EPS of ¥45.7 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.672%.
Which hedge fund is a major shareholder of KYORIN Pharmaceutical Co.,Ltd.?
Currently, no hedge funds are holding shares in JP:4569
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KYORIN Pharmaceutical Co.,Ltd.
KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents and intermediates. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. KYORIN Holdings, Inc. was founded in 1923 and is based in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
Nippon Shinyaku Co., Ltd.
―
Options Prices
Currently, No data available
---